­
­
­
­

Inventi Rapid - Novel Excipients

Articles

  • Inventi:pne/32954/20
    GOWARK AS A NOVEL PHARMACEUTICAL AGENT FOR THE ENHANCEMENT OF IN-VITRO CHARACTERISTICS OF POORLY ORAL BIOAVAILABLE NILOTINIB HCL
    Gurudath S, Basappa Veerabhadraiah Basavaraj*, Srinivasan Bharath

    The present study was designed to determine the biopotentiation effect of gowark on a poorly bioavailable oral anticancer drug nilotinib HCl with a versatile and biocompatible polymer. Nanoparticles of nilotinib HCl monohydrate were prepared by a single emulsion technique and solvent evaporation method using Eudragit S-100 as polymer along with gowark as a solubility and bioenhancer. The solubility of the drug got increased to 0.0051 mg/ml from 0.0023 mg/ml in the presence of gowark. The nanoparticles were evaluated for particle size, DSC, DLS, surface morphology, entrapment efficiency, residual dichloromethane content and in-vitro drug release studies. The drug entrapment efficiency was found to be in the range of 53.75 % to 96.25 % at an optimum polymer concentration. SEM studies revealed that surface of nanoparticles was almost porous and smooth with particles of spherical shape. Polydispersibility index, average particle size and zeta potential obtained from DLS and Zeta Sizer was in the range of 0.607 to 0.923, 634.4 nm and 379.9 nm and -9.05 and -6.43 indicating the uniform distribution of particles and stability without aggregation. In-vitro permeation profile of 88.40 % to 97.95 % at the end of 12 h was highly acceptable for the NESG, formulation with gowark compared to NES and marketed formulation. In conclusion, gowark a distilled cow urine could be a promising pharmaceutical excipient for enhancing the oral bioavailability of several drugs with poor oral absorption and aqueous solubility issues.

    How to Cite this Article
    Gurudath S, Basappa Veerabhadraiah Basavaraj, Srinivasan Bharath. Gowark as a Novel Pharmaceutical Agent for the Enhancement of In-Vitro Characteristics of Poorly Oral Bioavailable Nilotinib HCl. Inventi Rapid: Novel Excipients, 2021(1):1-7, 2020.
    Download Full Text